(Reuters) – European stocks edged higher on Wednesday as Britain approved a COVID-19 vaccine developed by AstraZeneca (NASDAQ:) and Oxford University, while bets of more U.S. fiscal aid and massive vaccination efforts spurred hopes of a strong global economic recovery next year.
The pan-European rose 0.1% by 0810 GMT, hovering near a 10-month high hit in the previous session.
Shares in AstraZeneca were up 1.3% after jumping 3.3% earlier in anticipation of the news. The drugmaker said the authorisation was for a two-dose regime, and that the vaccine had been approved for use for emergency supply as Britain battles a new, highly contagious variant of the virus.
Most markets in the region were subdued due to thin volumes in a holiday-shortened week. The German was flat, while French and Spanish stocks slipped 0.1% each.
Unicaja rose more than 2% and Liberbank was down 3.6% after they announced an all-in share deal that would create Spain’s fifth-biggest bank with around 110 billion euros ($134.71 billion) in assets.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.